Xbrane files three patent applications to further strengthen its proprietary low cost biosimilar platform technology

-Xbrane Biopharma AB (publ) ("Xbrane" or the "Company") (Nasdaq Stockholm: XBRANE) bases the development of its biosimilars on its patented platform technology ensuring higher yield and lower production cost compared to standard systems.

-Xbrane continuously innovates around its platform technology and will going forward expand the IP-portfolio protecting it.

-Xbrane has recently filed three patent applications covering novel nucleic acid sequences encoding various signal peptides that have been demonstrated to have significant impact on yield and thereby production cost of recombinant proteins.

"We are an innovative company continuously strengthening our platform technology with the focus of having the lowest production cost in the industry of the biosimilars we chose to do. Going forward we will put more emphasis on building an IP-portfolio around our platform technology to better protect and monetize on our research. The recently filed patents cover new inventions that further strengthen our platform", says Martin Åmark, CEO Xbrane.

Xbrane's low cost platform technology
Xbrane bases the development of its biosimilars on a patented platform technology providing higher yields and thereby lower production cost of high-quality recombinant proteins compared to standard systems. Xbrane works actively with its team of over 10 scientists to innovate around the platform and thereby further strengthen its competitive advantage as a biosimilar developer.

Xbrane has filed three patent applications for new inventions lowering production costs for biosimilars
Xbrane has recently filed three patent applications to the Swedish patent and Registration Office (PRV). The patent applications relate to novel methods of using signal peptides to enhance the production yield and thereby lowering the production cost of recombinant proteins. Recombinant proteins are produced via the introduction of a DNA-sequence into a living cell instructing it to produce the protein of interest, often the intended active ingredient in a pharmaceutical product. Signal peptides typically function to prompt a cell to translocate the recombinant protein, usually through and across the cellular membrane. It has been demonstrated in the recently filed patent applications that certain nucleic acid sequences of the DNA sequences encoding the signal peptides positively impact the production yield, i.e. the amount of the targeted recombinant protein produced at a given scale of fermentation. The recently filed patent applications relate to specific such novel nucleic acid sequences encoding various signal peptides that have been demonstrated to have significant impact on production yield. The ambition is to follow-up the patent applications with international patent applications with focus on commercially important jurisdictions such as USA, Europe, Japan and China. The recently filed patent applications are

jointly owned, at equal shares, by Xbrane and CloneOpt, a Stockholm University spin-out. The patent applications are part of several planned patent applications which the newly established IP department of Xbrane will file either alone or jointly with other companies to build a broader IP portfolio around Xbrane's platform technology.

Contacts

Martin Åmark, CEO
M: +46 (0) 763-093 777
E: martin.amark@xbrane.com

Susanna Helgesen, CFO
M: +46 (0) 708-278 636
E: susanna.helgesen@xbrane.com

About Us

Xbrane is a commercial phase Swedish biopharmaceutical company that develop and produces biosimilars. Xbrane has a patented protein production platform for development of biosimilars and world leading expertise in biosimilars. Xbrane's headquarter is located in Solna outside of Stockholm and the company's in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq Stockholm since September 2019 with the ticker XBRANE. For more information please visit www.xbrane.com.

Attachments

Xbrane files three patent applications to further strengthen its proprietary low cost biosimilar platform technology